Get the Stockscreener App
1.75
5.42%
+0.09
After Hours:
1.69
-0.06
-3.43%
Reneo Pharmaceuticals Inc stock is currently priced at $1.75, with a 24-hour trading volume of 203.21K.
It has seen a +5.42% increased in the last 24 hours and a -1.13% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.64 pivot point. If it approaches the $1.80 resistance level, significant changes may occur.
Previous Close:
$1.66
Open:
$1.61
24h Volume:
203.21K
Market Cap:
$58.49M
Revenue:
-
Net Income/Loss:
$-77.39M
P/E Ratio:
-0.7479
EPS:
-2.34
Net Cash Flow:
$-63.90M
1W Performance:
-3.31%
1M Performance:
-1.13%
6M Performance:
-74.11%
1Y Performance:
-77.71%
1D Range:
$1.61
$1.76
52W Range:
$0.9801
$9.45
Reneo Pharmaceuticals Inc Stock (RPHM) Company Profile
Name
Reneo Pharmaceuticals Inc
Sector
Industry
Phone
858-283-0280
Address
12230 El Camino Real, Suite 230, San Diego
Reneo Pharmaceuticals Inc Stock (RPHM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Reneo Pharmaceuticals Inc Stock (RPHM) Latest News
Insider Buying: Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Purchases 414281 Shares of Stock - Defense World
Defense World
Reneo Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying - Reneo Pharmaceuticals (NASDAQ:RPH - Benzinga
Benzinga
Reneo Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying By Benzinga - Investing.com UK
Investing.com UK
Analysts Set Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Price Target at $18.14 - Defense World
Defense World
Braden Michael Leonard Buys 414,281 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock - MarketBeat
MarketBeat
Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock ... - Yahoo New Zealand News
Yahoo New Zealand News
Reneo Pharmaceuticals Inc Stock (RPHM) Financials Data
Reneo Pharmaceuticals Inc (RPHM) Net Income 2024
RPHM net income (TTM) was -$77.39 million for the quarter ending December 31, 2023, a -48.95% decrease year-over-year.
Reneo Pharmaceuticals Inc (RPHM) Cash Flow 2024
RPHM recorded a free cash flow (TTM) of -$63.90 million for the quarter ending December 31, 2023, a -33.95% decrease year-over-year.
Reneo Pharmaceuticals Inc (RPHM) Earnings per Share 2024
RPHM earnings per share (TTM) was -$2.53 for the quarter ending December 31, 2023, a -19.34% decline year-over-year.
About Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):